# A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

> clinical trial · VERIFIED · 2026-07-20

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Chronic Myelogenous Leukemia - Chronic Phase

- Company: Novartis Pharmaceuticals
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07091019

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.